Focus Partners Wealth’s TG Therapeutics TGTX Stock Holding History

Focus Partners Wealth’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$489K	Sell	8,895 -51,665	-85%	-$2.11M	﹤0.01%	1974
2026 Q1	$2.01M	Buy	60,560 +1,785	+3%	+$53.2K	﹤0.01%	1310
2025 Q4	$1.75M	Buy	58,775 +4,123	+8%	+$135K	﹤0.01%	1381
2025 Q3	$1.97M	Sell	54,652 -4,388	-7%	-$145K	﹤0.01%	1019
2025 Q2	$2.12M	Buy	59,040 +23	+0%	+$856	﹤0.01%	883
2025 Q1	$2.33M	Buy	59,017 +2,323	+4%	+$78.2K	0.01%	809
2024 Q4	$1.71M	Buy	56,694 +194	+0.3%	+$5.57K	﹤0.01%	880
2024 Q3	$1.32M	Buy	+56,500	New	+$1.23M	﹤0.01%	879

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Focus Partners Wealth's TGTX Position: Q2 2026 in Review

Focus Partners Wealth reduced its TG Therapeutics (TGTX) stake by 85% in Q2 2026, selling an estimated $2.11M and leaving 8,895 shares worth $489K. The position accounts for ﹤0.01% of the portfolio, ranked #1974.

Focus Partners Wealth first reported a position in TGTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.33M in Q1 2025. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Focus Partners Wealth held 8,895 shares of TG Therapeutics worth $489K as of Q2 2026.
Focus Partners Wealth sold 51,665 TG Therapeutics shares in Q2 2026, an estimated $2.11M.
TG Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #1974 holding.
Focus Partners Wealth first reported a position in TG Therapeutics in Q3 2024 and has held it in 8 quarters since.
Focus Partners Wealth's TG Therapeutics position peaked at $2.33M in Q1 2025.
431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.